Advocacy

*January 2022* In this video, EGFR Resisters co-founder Jill Feldman discusses this topic with Dr. Jorge J Nieva of USC Norris Comprehensive Cancer Center.

*January 2022* In this video, EGFR Resisters co-founders Jill Feldman and Ivy Elkins gave a presentation about the clinical trial life cycle. It starts at about  1:50.

*December 2021* There is a growing cohort of younger adults who are being diagnosed with lung cancer under 40 years of age. Alarmingly, the research points to an increase not only in diagnosis at a young age—but particularly in women. Although the average age for a lung cancer diagnosis is…

*November 2021* In this webinar, Dr. Mark A. Socinski, Executive Medical Director, Advent Health Cancer Institute, Orlando, FL, will explain the process of participating in a lung cancer clinical trial from beginning to end. Dr. Socinski will explain how typical lung cancer clinical trials are structured, how patients are monitored…

*November 2021*   Listen to EGFR Resisters co-founder Jill Feldman's presentation at ASTRO — innovating for clinically meaningful benefits that matter to patients. The final session of the symposium was a lively debate on randomized clinical trials versus real world data. Four speakers offered points/counterpoints for randomized clinical trials versus…

*August 2021* It has been just over a year since we reported how oncogene-driven patient advocacy groups are disrupting the research paradigm in lung cancer.1 We have indeed come a long way since the discovery of the first EGFR mutation in lung cancer in 2004.2 ,3 Even amid the challenges of the global…